UPDATE 3-Bayer and Schering-Plough form drugs alliance
24676
Bayer AG forged an alliance for its struggling pharmaceuticals business with US drugmaker Schering-Plough on Monday, cutting costs and marking another step in the German company&#39;s transformation.
336979
Drugs firm Akzo Nobel will sell its drugs unit Organon BioSciences to Schering-Plough for 11bn euros.
196823
A potent new anti-clotting drug from Eli  Lilly and Co proved as safe and effective as Sanofi-Aventis's  top-seller Plavix in a mid-stage clinical trial, researchers  said on Sunday.  Now Lilly and its partner Sankyo Co. Ltd. aim to demonstrate  clear superiority for their compound, known as prasugrel or  CS-747, in a much larger Phase III study involving up to 13,000  patients that is about to get under way.
245551
Schering-Plough (SGP:NYSE - news - research) Monday announced a broad marketing agreement with Germany&#39;s Bayer (BAY:NYSE - news - research) that both companies said will lead to a more efficient use of their marketing and sales strengths.
338909
Germany&#39;s Bayer has agreed to sell its blood products business to US investment firms Cerberus and Ampersand Ventures for about $590 million as it continues to narrow the focus of its health-care business.
518270
AMSTERDAM -- Schering-Plough Corp. agreed to buy Akzo Nobel NV's drug-making division Organon for $14.4 billion to gain the world's third-largest maker of birth-control pills and a stable of experimental medicines.
359157
Schering-Plough Corp. paid $435 million in fines and pleaded guilty to criminal conspiracy charges to settle Justice Department accusations that it lied to the government about drug prices and improperly marketed cancer drugs for uses not approved by the Food and Drug Administration.
122773
The drugmaker Bayer AG said Friday that it will cut 6,100 jobs, or 5.5 percent of its work force, as it integrates Schering AG into its health care unit. More than half of the cuts will be in Europe, but about 1,000 positions will be eliminated in the United States.
456781
The Schering-Plough Corporation has agreed to pay $435 million and plead guilty to conspiracy to settle charges of marketing drugs for unapproved uses and overcharging Medicaid.
207911
Schering-Plough Corp.  on Monday said quarterly earnings more than doubled on growing demand for its Zetia and Vytorin cholesterol drugs and its treatments for arthritis and allergies, lifting shares 3.5 percent.
643039
Drug giant Schering-Plough Corp. said Monday that it will pay $10 million to exercise its option to license ViroPharma Inc.&#39;s cold treatment in the United States and Canada.
358404
Schering-Plough Corp  reported on Monday that third-quarter profit and sales rose, but still fell short of estimates, sending shares down 13 percent amid concerns about its flagship cholesterol drugs.
594500
Schering-Plough Corp. SGP.N on  Thursday reported a quarterly profit after a year-ago loss, as  positive foreign exchange trends helped offset poor sales of  its allergy and hepatitis drugs.
750251
BOSTON (CBS.MW) -- Pharmaceutical conglomerates Schering-Plough and Bayer have entered into a broad joint-marketing deal Monday for several of the companies&#39; leading drugs.
170214
BERLIN - Bayer AG, the German drug and chemical company, has agreed to sell its plasma products business for $590 million in cash and stock to the private US investment groups Cerberus Capital Management and Ampersand Ventures.
641779
Schering-Plough Corp.  on  Monday reported quarterly earnings far higher than Wall Street  expected, fueled by growing demand for its drugs against  cholesterol, arthritis, allergies and hepatitis C.
75799
Schering-Plough and Merck posted strong sales from their joint venture in cholesterol drugs, but otherwise their third-quarter earnings were notably different.